Incretin-based therapies, such as glucagon-like peptide-1 receptor agonists, are widely prescribed for obesity and induce substantial weight loss. However, there is growing concern about their effe... Background: Incretin-based therapies induce substantial weight loss and are widely prescribed; disproportionate losses in fat-free mass (FFM) and skeletal muscle are a concern. Purpose: To evaluate...